Takeda begins Phase 3 trial for TAK-875 in Type 2 diabetes patients
TAK-875 is a selective agonist of GPR40, one of the G-protein-coupled receptors that are expressed in pancreatic islet cells. The first double-blind, randomized, 24-week Phase 3 trial in
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.